Serving Society
While Shen Qi continued his exercise regimen, he received a rat experiment report from Ou Beiqi Pharmaceutical regarding compound C01C.
Animal experimental data showed that in emaciated mice, when the doses were 1 mg/kg and 3 mg/kg, the blood drug levels were 190 nmol/L and 600 nmol/L, respectively, and the plasma activity inhibition rates reached 69% and 84%, respectively.
The plasma half-life of C01C in rats is 1.7 h, the oral bioavailability is 68%, and the clearance rate is 60 ml/(min*kg). Systemic clearance is mainly achieved by the kidneys as the intact parent drug, and partial clearance can also be achieved through bile excretion and physiological metabolism.
Animal experimental data indicate that, if rodents are used as experimental subjects, CO1C is a compound that can be used to treat diabetes.
This aligns somewhat with reports from Europe, but after the Swiss research team entered the clinical trial phase, they concluded that their compound was more suitable for treating Alzheimer's disease.
This is not contradictory. Glycogen synthase kinase-3β is a target associated with a variety of diseases. Based on this research conclusion, glycogen synthase kinase-3β inhibitors developed in Europe and China may have different characteristics.
In fact, the animal experiments conducted by Ou Beiqi Pharmaceutical have only just begun, with several more mouse experiments, as well as monkey and dog experiments to follow.
Only after all experiments on mice, monkeys, and dogs are completed can the process team at Ou Beiqi Pharmaceutical and its behind-the-scenes executives determine which target C01C targets and whether it is necessary to proceed to Phase I clinical trials.
Shen Qi sent a telegram to the Nangang authorities. "The results are encouraging; keep up the good work."
After sending the telegram, Shen Qi went to the Yenching University Volunteer Service Center and led a team to a nursing home in the SJS district.
At last year's joint meeting of the Party and government leaders of Yenching University, Shen Qi volunteered to take on the responsibility of social service. He mentioned at the meeting that "when poor, one should cultivate one's own virtue; when successful, one should benefit all under heaven." Scholars with profound knowledge should serve society more broadly.
Yenching University has always had a variety of volunteer service clubs, most of which are student clubs, but there are also faculty and staff volunteer associations.
Yenching University selected more than a dozen outstanding students from various departments to form the "Shen Qi Volunteer Service Team," with Shen Qi as the team leader.
The "Shen Qi Volunteer Service Team" has carried out numerous activities in the past six months, including organizing blood donation drives, providing educational support in impoverished mountainous areas, and serving people with disabilities.
Today, led by team leader Shen Qi, they visited the nursing home to comfort the elderly and provide them with welfare benefits.
Shen Qi noticed a new member in the team. She was a newly joined volunteer, but she had already met Shen Qi before, so they weren't strangers.
"Linna, you are so energetic, you are everywhere," Shen Qi said to the new member Zeng Linna.
Zeng Linna smiled and said, "I have to come to the SJS district's social service activities because I grew up here."
"Are you a kid from the compound?" Shen Qi asked. SJS District is a small area on the outskirts of the capital. Although it is small, it is quite unique.
"Yes, I'm a kid from the compound." Zeng Linna nodded, a look of fond reminiscence on her face. "The kids in our compound grew up eating food from everyone's homes. We played together all the time, and sometimes we'd stay at a friend's house when it got late. As for whether the kid who barged into our house was doing well in school, whether he could get into a top middle school, or whether he would lead our own kids astray, the parents never cared. In their eyes, a child is a child, and he should have the innocence and joy that children should have."
"It seems you had a very happy childhood," Shen Qi said with a smile.
"My best friend in the compound was Duoduo. Her parents were often away from home due to work, so she was raised by her grandparents. Duoduo's grandma was incredibly kind. If she saw a security guard dressed in thin clothes, she would find some warm clothes and quietly give them to him. If we encountered beggars on the street, the old lady would have Duoduo and me buy some steamed buns and a bowl of porridge to give to them. The old lady was full of love for everyone. She believed that if everyone gave a little love, the world would become a better place." Zeng Linna recounted her childhood, which she spent in a healthy and harmonious environment.
"What a positive old lady! She'll surely live a long and healthy life," Shen Qi remarked with great interest.
"Grandma is eighty years old this year..." Zeng Linna said, then suddenly her smile turned sad, "Grandma lives in this nursing home now, and her home is only a kilometer away from here."
"..." Shen Qi was silent for a moment, then asked, "What about Grandma's children? What about your best friend's parents?"
"My best friend's parents are still busy. Her grandmother has three sons and a daughter, but she now lives in a nursing home. Her husband has also passed away, and she is all alone." Zeng Linna became increasingly melancholy.
"Come on, take me to see this old lady." Shen Qi sighed. It was quite ironic that this old lady, who had spent her life doing good deeds, caring for others, and spreading positive energy, was now unable to enjoy the care of her children.
"No matter what, I prefer to believe that there is more love than hate in the world, and that kind people will eventually be rewarded. That's why I joined the volunteer association. I want to do what I can for those in need." Zeng Linna's saintly aura shines brightly. Her upbringing and the things she has experienced have made her somewhat different from others.
"That's right, good deeds will be rewarded, perhaps the time hasn't come yet." Shen Qi and Zeng Linna approached an old lady.
The old lady sat quietly in the chair, wrapped in thick autumn clothes despite the sweltering heat. Her face was like a statue, wrinkled and expressionless.
The arrival of Shen Qi and Zeng Linna did not cause the old lady's emotions to fluctuate in the slightest. She just sat there, motionless and silent.
Zeng Linna knelt on one knee in front of the old lady and said softly, "Grandma, I've come to see you."
The old lady glanced at Zeng Linna and finally spoke, "Yulan, it's cold this winter, and you're not very healthy, so you need to keep warm."
Zeng Linna's eyes instantly welled up with tears. She murmured, "Grandma, it's me, it's Nana from the Zeng Baldy's family..."
The old lady said, "Little Li gave me a painting yesterday. It's a portrait of Chairman Mao, and it's very well done."
Tears streamed down Zeng Linna's face. The "Little Li" the old lady had mentioned had passed away five or six years ago.
Her memory was confused, and her words were incoherent... After observing her for a long time, Shen Qi could roughly determine that the old lady had Alzheimer's disease.
Alzheimer's disease, also known as senile dementia, is causing a surge in the number of people suffering from this disease as the global elderly population rapidly increases, spreading to every corner of the world.
Alzheimer's disease and other types of dementia are not part of normal aging. China has an elderly population of 300 million, and the number of Alzheimer's disease is enormous.
Although scientists have discovered the pathogenic mechanisms of Alzheimer's disease, there is still a long way to go before finding a cure.
Pharmaceutical giants such as Johnson & Johnson, Pfizer, and Eli Lilly have invested heavily in the research and development of Alzheimer's disease's drugs, but all have failed.
Roche's multi-million dollar research and development of the anti -Alzheimer's disease's drug Gantenerumab failed in its Phase I Clinical Trial, its closest attempt to success to date, yet it still failed.
Currently, the team at Novartis in Switzerland is considered the most promising candidate. Three years ago, they completed a Phase II clinical trial in Europe for an Alzheimer's disease's drug, but the subsequent test results are unknown and have not been publicly reported to date.
The development of drugs for Alzheimer's disease has become a huge pit, a bottomless black hole.
Zeng Linna sobbed softly, but the old lady remained unmoved.
Shen Qi saw this and felt uneasy.
Shen Qi didn't know if his C01C would be successful, but he desperately wanted to succeed.
Whether it's Alzheimer's disease, diabetes, or an autoimmune disease, as long as CO1C can cure one of these diseases, Shen Qi will be satisfied.